Jonathan R. Goodman - Net Worth and Insider Trading

Jonathan R. Goodman Net Worth

The estimated net worth of Jonathan R. Goodman is at least $523,400 dollars as of 2024-11-13. Jonathan R. Goodman is the Director of POINT Biopharma Global Inc and owns about 41,872 shares of POINT Biopharma Global Inc (PNT) stock worth over $523,400. Details can be seen in Jonathan R. Goodman's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Jonathan R. Goodman has not made any transactions after 2022-11-18 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Jonathan R. Goodman

Jonathan R. Goodman Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jonathan R. Goodman owns 1 companies in total, including POINT Biopharma Global Inc (PNT) .

Click here to see the complete history of Jonathan R. Goodman’s form 4 insider trades.

Insider Ownership Summary of Jonathan R. Goodman

Ticker	Comapny	Transaction Date	Type of Owner
PNT	POINT Biopharma Global Inc	2022-11-18	director

Jonathan R. Goodman Latest Holdings Summary

Jonathan R. Goodman currently owns a total of 1 stock. Jonathan R. Goodman owns 41,872 shares of POINT Biopharma Global Inc (PNT) as of November 18, 2022, with a value of $523,400.

Latest Holdings of Jonathan R. Goodman

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
PNT	POINT Biopharma Global Inc	2022-11-18	41,872	12.50	523,400

Holding Weightings of Jonathan R. Goodman

Jonathan R. Goodman Form 4 Trading Tracker

According to the SEC Form 4 filings, Jonathan R. Goodman has made a total of 1 transactions in POINT Biopharma Global Inc (PNT) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in POINT Biopharma Global Inc is the acquisition of 6,000 shares on November 18, 2022, which cost Jonathan R. Goodman around $37,980.

Insider Trading History of Jonathan R. Goodman

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jonathan R. Goodman Trading Performance

GuruFocus tracks the stock performance after each of Jonathan R. Goodman's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jonathan R. Goodman is 16.8%. GuruFocus also compares Jonathan R. Goodman's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jonathan R. Goodman within 3 months outperforms 1 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Jonathan R. Goodman's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Jonathan R. Goodman

Average Return

Average return per transaction

Outperforming Transactions

1 out of 1 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	1.85
Relative Return to S&P 500(%)	4.7

Jonathan R. Goodman Ownership Network

Ownership Network List of Jonathan R. Goodman

No Data

Ownership Network Relation of Jonathan R. Goodman

Jonathan R. Goodman Owned Company Details

What does POINT Biopharma Global Inc do?

Who are the key executives at POINT Biopharma Global Inc?

Jonathan R. Goodman is the director of POINT Biopharma Global Inc. Other key executives at POINT Biopharma Global Inc include other: See Explanation of Responses Biotechnology Value Fund L P , 10 percent owner Bvf Partners L P/il , and 10 percent owner Bvf Gp Holdings Llc .

POINT Biopharma Global Inc (PNT) Insider Trades Summary

Over the past 18 months, Jonathan R. Goodman made no insider transaction in POINT Biopharma Global Inc (PNT). Other recent insider transactions involving POINT Biopharma Global Inc (PNT) include a net sale of 17,161,278 shares made by Biotechnology Value Fund L P ,

In summary, during the past 3 months, insiders sold 0 shares of POINT Biopharma Global Inc (PNT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 17,161,278 shares of POINT Biopharma Global Inc (PNT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 17,161,278 shares.

POINT Biopharma Global Inc (PNT)'s detailed insider trading history can be found in Insider Trading Tracker table.

POINT Biopharma Global Inc Insider Transactions

No Available Data

Jonathan R. Goodman Mailing Address

Above is the net worth, insider trading, and ownership report for Jonathan R. Goodman. You might contact Jonathan R. Goodman via mailing address: 4850 West 78th Street, Indianapolis In 46268.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.